Replies to post #221170 on ORIONS Money Stocks

[AugustaFriends]

CYTK watch for .79 Break - CYTK[t][/t] is trading slightly above cash value with $89M in cash.
Little downside risk since dilution already occurred.
Chart / technicals show upward trend.
Increase in buying / volume.
Partnered with Amgen on some studies.

What is expect 2nd half of 2012?
1.) data from CY4023 for generalized myasthenia gravis from phase 2a
2.) initiation of CY4026 in phase 2b
3.) completion of discussions w FDA regarding tirasemtiv for ALS
4.) IND for CK-2127107
5.) decision regarding progression of ATOMIC-AHF clinical trial
6.) finalization of phase 2 protocol w/ Amgen of omecamtiv mecarbil for heart failure

Just a matter of time before CYTK is trading above $1 again.
COWEN has an outperform rating on this with a $2 price target.